Biotechnology

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

Arrotex secures rights to an innovative, FDA-approved nanotech eye drop, promising faster, simpler recovery for thousands of surgical patients.

A landmark partnership aims to slash BCI development costs from $100M to $5M, accelerating therapies and the quest for a human brain AI model.

With a major capital infusion, the biotech firm will accelerate its lead drug for Eosinophilic Esophagitis and expand its innovative Diffusphere™ platform.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

Sōlaria Biō’s new study validates a microbe-based medical food, Bōndia™, offering a novel, science-backed approach to bone loss for millions of women.

With its NAD+ technology featured in Forbes, biotech brand Aramore is challenging marketing hype with scientific rigor and a vision for longevity.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

A new partnership will supply Japan's surging cell therapy sector with critical, GMP-grade materials, aiming to accelerate the path from lab to clinic.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A novel implant activating the body's own pathways could offer a safer, more effective alternative to traditional hormone therapies for breast cancer.

Meet the three brilliant researchers whose work in non-invasive surgery, cardiac robotics, and smart sensors just earned them a prestigious $250,000 prize.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.